TY - JOUR
T1 - Plasmodium falciparum apicomplexan-specific glucosamine-6-phosphate n-acetyltransferase is key for amino sugar metabolism and asexual blood stage development
AU - Chi, Jordi
AU - Cova, Marta
AU - De Las Rivas, Matilde
AU - Medina, Ana
AU - Junqueira Borges, Rafael
AU - Leivar, Pablo
AU - Planas, Antoni
AU - Usón, Isabel
AU - Hurtado-Guerrero, Ramón
AU - Izquierdo, Luis
N1 - Funding Information:
We acknowledge support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. This research is part of the ISGlobal’s Program on the Molecular Mechanisms of Malaria, which is partially supported by the Fundación Ramón Areces.
Funding Information:
J.C. and M.C. were supported by an SAF2016-76080-R grant from the Spanish Ministry of Economy (AEI/FEDER, UE) to L. I. Research has also received funding from a Spanish Ministry of Science & Innovation grant PID2019-110810RB-I00 to L.I. L.I. and M.C. are members of the GlycoPar-EU FP7-funded Marie Curie Initial Training Network (GA 608295). I.U. was supported by grants PGC2018-101370-B-I00 and MDM2014-0435-01 from the Spanish Ministry of Science and Innovation and EU FEDER funds. A.M. was supported by fellowship BES-2017-080368 from the Spanish Ministry of Science and Innovation and R.J.B. was supported by a FAPESP 2016/24191-8 grant. R. H.-G. acknowledges ALBA Light Source (Barcelona, Spain) synchrotron beamline XALOC. He also acknowledges ARAID, MEC (CTQ2013-44367-C2-2-P, BFU2016-75633-P and PID2019-105451GB-I00) and Gobierno de Aragón (E34_R17 and LMP58_18) with FEDER (2014 –2020) funds for “Building Europe from Aragón” for financial support. The research leading to these results has also received funding from FP7 442 (2007–2013) under BioStruct-X (grant agreement no. 283570 and BIOSTRUCTX_5186). A.P. acknowledges grant GLYCO2ZYMES (BFU2016-77427) from MICINN and P.L. acknowledges funds from URL/“Obra Social la Caixa.”
Publisher Copyright:
© 2020 Chi et al.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and Nand O-linked glycans. Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate Nacetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s. By using conditional genetic engineering, we demonstrate the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual Plasmodium falciparum parasites. Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1. The indepth analysis of the crystal shows the presence of specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants. The experiments reveal distinct features in apicomplexan GNA1 enzymes that could be exploitable for the generation of selective inhibitors against these parasites, by targeting the hexosamine pathway. This work underscores the potential of apicomplexan GNA1 as a drug target against malaria. IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy. The absence of treatments, the emergence of resistances against available therapies, and the parasite’s ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites. We demonstrate that glucosamine-6-phosphate N-acetyltransferase (GNA1), required for the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), is essential for P. falciparum asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle. The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite C. parvum, used here as a surrogate, highlights significant differences from human GNA1. These divergences can be exploited for the design of specific inhibitors against the malaria parasite.
AB - UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and Nand O-linked glycans. Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate Nacetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s. By using conditional genetic engineering, we demonstrate the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual Plasmodium falciparum parasites. Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1. The indepth analysis of the crystal shows the presence of specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants. The experiments reveal distinct features in apicomplexan GNA1 enzymes that could be exploitable for the generation of selective inhibitors against these parasites, by targeting the hexosamine pathway. This work underscores the potential of apicomplexan GNA1 as a drug target against malaria. IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy. The absence of treatments, the emergence of resistances against available therapies, and the parasite’s ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites. We demonstrate that glucosamine-6-phosphate N-acetyltransferase (GNA1), required for the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), is essential for P. falciparum asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle. The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite C. parvum, used here as a surrogate, highlights significant differences from human GNA1. These divergences can be exploited for the design of specific inhibitors against the malaria parasite.
KW - Aminosugar pathway
KW - Apicomplexan parasites
KW - Malaria
KW - Metabolism
KW - Plasmodium falciparum
KW - UDP-N-acetylglucosamine
UR - http://www.scopus.com/inward/record.url?scp=85094171493&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_univeritat_ramon_llull&SrcAuth=WosAPI&KeyUT=WOS:000579503600053&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1128/mBio.02045-20
DO - 10.1128/mBio.02045-20
M3 - Article
C2 - 33082260
AN - SCOPUS:85094171493
SN - 2161-2129
VL - 11
SP - 1
EP - 15
JO - mBio
JF - mBio
IS - 5
M1 - e02045-20
ER -